



AnGes

FY2026-1Q Financial Results Summary



May 2026

Major Business Highlights for FY2026-1Q

【 HGF Gene Therapy Product 】 : Advancing BLA Preparation in the US

US : Clinical trials have been completed, and preparation for the Biologics License Application (BLA) is underway in consultation with the FDA.

Type B Clinical Meeting with the FDA was conducted.

→Agreement was reached on the regulatory strategy related to clinical matters.

JP : Future actions are under consideration based on progress in the US

【NF- κ B Decoy Oligonucleotide DNA】 : P2Clinical Trial Ongoing in Japan

Results from the P1 clinical trial in the US were published in *The SPINE Journal*, the official journal of the North American Spine Society.

In Japan, patient enrollment for the Phase II clinical trial is progressing.

【Tie2 Receptor Agonist】 : P2 Clinical Trial for ARDS Ongoing in the US

In the P2 clinical trial in the United States, planned patient enrollment has been completed.

→ Additional enrollment is ongoing to compensate for drop-out cases.

The first patient dosing has been completed in an investigator-initiated trial evaluating improvement of cognitive impairment in hemodialysis patients.

【Zokinvy】 : Sales Progressing Largely in Line with Plan

Major Business Highlights for FY2026-1Q

【ACRL】 : Order Intake for Expanded Newborn Screening Remains Stable

- Expanded Newborn Screening

The number of target diseases has expanded from 9 to 14, and order intake remains stable, operating at near full capacity.

- Establishment of a Comprehensive Testing Framework

A comprehensive testing system has been developed, covering processes from diagnosis to treatment of rare genetic diseases.

The scope of genetic testing target diseases has been expanded

→ In addition to HGPS and PDPL, seven diseases included in expanded newborn screening have been newly added.

Research on the use of biomarker testing as secondary screening has been published in a scientific journal.

【EmendoBio】 : Expansion of Research Outcomes on OMNI Nuclease to the US

Efforts are underway to establish an operational framework to promote research and development activities and academic publications in the US.

Joint research with Stanford University is being advanced on novel cancer genome therapies.

Consideration is being given to establishing new research and development sites in the US.

Performance for FY2026-1Q

**Business revenue increased,
while operating expenses rose due to HGF application preparation costs**

(Unit : Million Yen)

	FY2025-1Q	FY2026-1Q	Change
Revenue	169	203	34
Operating Expenses	1,424	1,700	275
Operating Profit(Loss)	-1,255	-1,496	-241
Non Operating Income(Expenses)	17	386	368
Ordinary Profit(Loss)	-1,237	-1,110	127
Extraordinary Income(Expenses)	0	0	0
Net Profit(Loss)	-1,247	-1,082	165

Revenue (YoY+20.4%)

- Expanded newborn screening testing at ACRL totaled 124 millionYen (YoY+9..7%)
- Zokinvy sales amounted to 78 millionYen (YoY+42.4%)

Operating Expenses (YoY+19.3%)

- Cost of Sales: 121 millionYen (YoY +8 millionYen)
Increase mainly due to higher cost of sales for Zokinvy
- R&D Expenses: 1,007 millionYen (YoY+217 millionYen)
Increase primarily attributable to higher costs related to HGF application preparation
- SGA Expenses: 571 millionYen (YoY+49millionYen)
Increase mainly due to higher taxes and dues at EmendoBio

Non Operating Income (YoY368millionYen)

- Foreign exchange gain of 385 millionYen from the revaluation of a loan to EmendoBio.

Consolidated Balance Sheet Highlights

(Unit : Million Yen)

	Dec-2025	March-2026	Change
Current Assets	4,386	3,367	-1,018
Cash and Deposits	1,882	835	-1,046
Non-Current Assets	1,019	1,104	84
Total Assets	5,405	4,472	-933
Liabilities	2,329	2,448	118
Net Assets	3,076	2,023	-1,052

Current Assets

- 414 millionYen was raised through the issuance of the 46th series of stock acquisition rights.
- Current assets decreased by 1,018 millionYen due to expenditures such as operating expenses.

Net Assets

- As a result of the exercise of the 46th series of stock acquisition rights, capital stock and capital surplus each increased by 211 millionYen.
- Net assets decreased by 1,052 millionYen due to the quarterly net loss.

Genetic Innovation for All



<https://www.anges.co.jp/en>